Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles.
Animals
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Cell Line, Tumor
Cell-Derived Microparticles
/ immunology
Drug Carriers
/ pharmacology
Drug Synergism
Female
Humans
Immune Checkpoint Inhibitors
/ pharmacology
Immunologic Memory
Male
Metformin
/ pharmacology
Mice
Neoplasms
/ drug therapy
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
RAW 264.7 Cells
Tumor Escape
/ drug effects
Tumor Microenvironment
/ drug effects
Tumor-Associated Macrophages
/ drug effects
Xenograft Model Antitumor Assays
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
19 01 2021
19 01 2021
Historique:
received:
18
02
2020
accepted:
10
12
2020
entrez:
20
1
2021
pubmed:
21
1
2021
medline:
2
2
2021
Statut:
epublish
Résumé
The main challenges for programmed cell death 1(PD-1)/PD-1 ligand (PD-L1) checkpoint blockade lie in a lack of sufficient T cell infiltration, tumor immunosuppressive microenvironment, and the inadequate tumor accumulation and penetration of anti-PD-1/PD-L1 antibody. Resetting tumor-associated macrophages (TAMs) is a promising strategy to enhance T-cell antitumor immunity and ameliorate tumor immunosuppression. Here, mannose-modified macrophage-derived microparticles (Man-MPs) loading metformin (Met@Man-MPs) are developed to efficiently target to M2-like TAMs to repolarize into M1-like phenotype. Met@Man-MPs-reset TAMs remodel the tumor immune microenvironment by increasing the recruitment of CD8
Identifiants
pubmed: 33469052
doi: 10.1038/s41467-020-20723-x
pii: 10.1038/s41467-020-20723-x
pmc: PMC7815730
doi:
Substances chimiques
Drug Carriers
0
Immune Checkpoint Inhibitors
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Metformin
9100L32L2N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
440Références
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
J Clin Invest. 2007 Dec;117(12):3833-45
pubmed: 17992258
Nano Lett. 2017 Dec 13;17(12):7684-7690
pubmed: 29160717
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10000-5
pubmed: 15220480
J Clin Invest. 2015 Sep;125(9):3384-91
pubmed: 26325035
Mol Ther. 2017 Jul 5;25(7):1665-1675
pubmed: 28284981
J Cell Sci. 2005 May 15;118(Pt 10):2325-40
pubmed: 15870107
Adv Drug Deliv Rev. 2017 May 15;114:206-221
pubmed: 28449873
Nat Nanotechnol. 2019 Sep;14(9):891-901
pubmed: 31384037
Angew Chem Int Ed Engl. 2015 Jan 12;54(3):1036-40
pubmed: 25412570
Oncotarget. 2017 Mar 28;8(13):20706-20718
pubmed: 28157701
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):180-185
pubmed: 26621196
Hepatology. 2019 Jul;70(1):198-214
pubmed: 30810243
Cell. 2010 Apr 2;141(1):52-67
pubmed: 20371345
Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt A):1989-2000
pubmed: 28578911
J Immunother Cancer. 2018 Jan 23;6(1):8
pubmed: 29357948
J Control Release. 2018 May 28;278:110-121
pubmed: 29630987
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):148-156
pubmed: 26928656
J Control Release. 2016 Oct 28;240:202-211
pubmed: 26686082
Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E4041-E4050
pubmed: 29632196
Nat Protoc. 2011 Aug 18;6(9):1355-66
pubmed: 21886101
Cell. 2016 Mar 10;164(6):1226-1232
pubmed: 26967288
Nat Commun. 2012;3:1282
pubmed: 23250412
Nat Commun. 2018 Feb 8;9(1):582
pubmed: 29422500
J Leukoc Biol. 2009 Nov;86(5):1065-73
pubmed: 19741157
ACS Nano. 2018 Sep 25;12(9):8977-8993
pubmed: 30133260
Adv Drug Deliv Rev. 2015 Dec 1;95:50-5
pubmed: 26482189
Nat Biomed Eng. 2019 Sep;3(9):729-740
pubmed: 31110292
J Clin Oncol. 2017 May 1;35(13):1421-1429
pubmed: 28375706
Med Res Rev. 2019 Jan;39(1):265-301
pubmed: 30215856
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
J Clin Invest. 2012 Mar;122(3):899-910
pubmed: 22293174
Trends Biochem Sci. 2018 Dec;43(12):1014-1032
pubmed: 30287140
Cancer Res. 2011 Jul 1;71(13):4366-72
pubmed: 21540236
J Exp Clin Cancer Res. 2019 Jun 4;38(1):235
pubmed: 31164151
Front Immunol. 2018 Jul 03;9:1534
pubmed: 30018618
Tissue Barriers. 2015 May 06;3(3):e1037418
pubmed: 26451342
EMBO Mol Med. 2018 Dec;10(12):
pubmed: 30442705
Nat Commun. 2019 Jun 4;10(1):2450
pubmed: 31164648
Oncotarget. 2015 Nov 3;6(34):36441-55
pubmed: 26497364
Pharmacol Res. 2016 Nov;113(Pt A):675-685
pubmed: 27720766
Cell Metab. 2018 Nov 6;28(5):679-688.e4
pubmed: 30244975
Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6506-14
pubmed: 26604307
Theranostics. 2020 May 17;10(15):6581-6598
pubmed: 32550891
Cancer Res. 2009 Oct 1;69(19):7507-11
pubmed: 19752085
Immunity. 2016 Jun 21;44(6):1255-69
pubmed: 27332730
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Gut. 2019 Oct;68(10):1764-1773
pubmed: 30661053
Nat Commun. 2019 Jun 11;10(1):2416
pubmed: 31186412
Cancer Res. 2016 Feb 1;76(3):513-6
pubmed: 26772756
Trends Mol Med. 2016 Jun;22(6):448-451
pubmed: 27174038
Cancer Cell. 2014 Jun 16;25(6):846-59
pubmed: 24898549
Sci Transl Med. 2019 Jan 9;11(474):
pubmed: 30626714
Cell Res. 2016 Jun;26(6):713-27
pubmed: 27167569
Leukemia. 2006 Sep;20(9):1487-95
pubmed: 16791265
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830
ACS Nano. 2017 Jan 24;11(1):69-83
pubmed: 28068069
Br J Cancer. 2007 Aug 6;97(3):358-67
pubmed: 17609667